Access the full text.
Sign up today, get DeepDyve free for 14 days.
( DoshiJ. A. HodgkinsP. KahleJ. SikiricaV. CangelosiM. J. SetyawanJ. ErderM. H. NeumannP. J. (2012). Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. Journal of the American Academy of Child & Adolescent Psychiatry, 51(10), 990–1002.23021476)
DoshiJ. A. HodgkinsP. KahleJ. SikiricaV. CangelosiM. J. SetyawanJ. ErderM. H. NeumannP. J. (2012). Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. Journal of the American Academy of Child & Adolescent Psychiatry, 51(10), 990–1002.23021476DoshiJ. A. HodgkinsP. KahleJ. SikiricaV. CangelosiM. J. SetyawanJ. ErderM. H. NeumannP. J. (2012). Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. Journal of the American Academy of Child & Adolescent Psychiatry, 51(10), 990–1002.23021476, DoshiJ. A. HodgkinsP. KahleJ. SikiricaV. CangelosiM. J. SetyawanJ. ErderM. H. NeumannP. J. (2012). Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. Journal of the American Academy of Child & Adolescent Psychiatry, 51(10), 990–1002.23021476
( American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). American Psychiatric Association.)
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). American Psychiatric Association.American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). American Psychiatric Association., American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). American Psychiatric Association.
J. Doshi, P. Hodgkins, J. Kahle, V. Sikirica, M. Cangelosi, J. Setyawan, M. Erder, P. Neumann (2012)
Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.Journal of the American Academy of Child and Adolescent Psychiatry, 51 10
(2020)
Interactive drug analysis profiles
( CorteseS. AdamoN. Del GiovaneC. Mohr-JensenC. HayesA. J. CarucciS. AtkinsonL. Z. TessariL. BanaschewskiT. CoghillD. HollisC. SimonoffE. ZuddasA. BarbuiC. PurgatoM. SteinhausenH-C. ShokranehF. XiaJ. CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738.30097390)
CorteseS. AdamoN. Del GiovaneC. Mohr-JensenC. HayesA. J. CarucciS. AtkinsonL. Z. TessariL. BanaschewskiT. CoghillD. HollisC. SimonoffE. ZuddasA. BarbuiC. PurgatoM. SteinhausenH-C. ShokranehF. XiaJ. CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738.30097390CorteseS. AdamoN. Del GiovaneC. Mohr-JensenC. HayesA. J. CarucciS. AtkinsonL. Z. TessariL. BanaschewskiT. CoghillD. HollisC. SimonoffE. ZuddasA. BarbuiC. PurgatoM. SteinhausenH-C. ShokranehF. XiaJ. CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738.30097390, CorteseS. AdamoN. Del GiovaneC. Mohr-JensenC. HayesA. J. CarucciS. AtkinsonL. Z. TessariL. BanaschewskiT. CoghillD. HollisC. SimonoffE. ZuddasA. BarbuiC. PurgatoM. SteinhausenH-C. ShokranehF. XiaJ. CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738.30097390
( OpenPrescribing. (2020). Tariff prices for Dexamfetamine 5mg tablets. https://openprescribing.net/tariff/?codes=0404000L0AAAJAJ)
OpenPrescribing. (2020). Tariff prices for Dexamfetamine 5mg tablets. https://openprescribing.net/tariff/?codes=0404000L0AAAJAJOpenPrescribing. (2020). Tariff prices for Dexamfetamine 5mg tablets. https://openprescribing.net/tariff/?codes=0404000L0AAAJAJ, OpenPrescribing. (2020). Tariff prices for Dexamfetamine 5mg tablets. https://openprescribing.net/tariff/?codes=0404000L0AAAJAJ
( Care Quality Commission. (2016). The safer management of controlled drugs. Annual report 2015. https://www.cqc.org.uk/sites/default/files/20160714_controlleddrugs2015_report.pdf)
Care Quality Commission. (2016). The safer management of controlled drugs. Annual report 2015. https://www.cqc.org.uk/sites/default/files/20160714_controlleddrugs2015_report.pdfCare Quality Commission. (2016). The safer management of controlled drugs. Annual report 2015. https://www.cqc.org.uk/sites/default/files/20160714_controlleddrugs2015_report.pdf, Care Quality Commission. (2016). The safer management of controlled drugs. Annual report 2015. https://www.cqc.org.uk/sites/default/files/20160714_controlleddrugs2015_report.pdf
( RamanS. R. ManK. C. BahmanyarS. BerardA. BilderS. BoukhrisT. BushnellG. CrystalS. FuruK. KaoYangY-H. KarlstadØ. KielerH. KubotaK. Cheng LaiE-C. MartikainenJ. E. MauraG. MooreN. MonteroD. NakamuraH. , . . . WongI. C. K. (2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. The Lancet Psychiatry, 5(10), 824–835.30220514)
RamanS. R. ManK. C. BahmanyarS. BerardA. BilderS. BoukhrisT. BushnellG. CrystalS. FuruK. KaoYangY-H. KarlstadØ. KielerH. KubotaK. Cheng LaiE-C. MartikainenJ. E. MauraG. MooreN. MonteroD. NakamuraH. , . . . WongI. C. K. (2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. The Lancet Psychiatry, 5(10), 824–835.30220514RamanS. R. ManK. C. BahmanyarS. BerardA. BilderS. BoukhrisT. BushnellG. CrystalS. FuruK. KaoYangY-H. KarlstadØ. KielerH. KubotaK. Cheng LaiE-C. MartikainenJ. E. MauraG. MooreN. MonteroD. NakamuraH. , . . . WongI. C. K. (2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. The Lancet Psychiatry, 5(10), 824–835.30220514, RamanS. R. ManK. C. BahmanyarS. BerardA. BilderS. BoukhrisT. BushnellG. CrystalS. FuruK. KaoYangY-H. KarlstadØ. KielerH. KubotaK. Cheng LaiE-C. MartikainenJ. E. MauraG. MooreN. MonteroD. NakamuraH. , . . . WongI. C. K. (2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. The Lancet Psychiatry, 5(10), 824–835.30220514
( Bolea-AlamañacB. NuttD. J. AdamouM. AshersonP. BazireS. CoghillD. HealD. MüllerU. NashJ. SantoshP. SayalK. Sonuga-BarkeE. YoungS. J. , & for the Consensus Group (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(3), 179–203.24526134)
Bolea-AlamañacB. NuttD. J. AdamouM. AshersonP. BazireS. CoghillD. HealD. MüllerU. NashJ. SantoshP. SayalK. Sonuga-BarkeE. YoungS. J. , & for the Consensus Group (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(3), 179–203.24526134Bolea-AlamañacB. NuttD. J. AdamouM. AshersonP. BazireS. CoghillD. HealD. MüllerU. NashJ. SantoshP. SayalK. Sonuga-BarkeE. YoungS. J. , & for the Consensus Group (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(3), 179–203.24526134, Bolea-AlamañacB. NuttD. J. AdamouM. AshersonP. BazireS. CoghillD. HealD. MüllerU. NashJ. SantoshP. SayalK. Sonuga-BarkeE. YoungS. J. , & for the Consensus Group (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(3), 179–203.24526134
A. Turgay, D. Goodman, P. Asherson, R. Lasser, Thomas Babcock, Michael Pucci, R. Barkley (2012)
Lifespan persistence of ADHD: the life transition model and its application.The Journal of clinical psychiatry, 73 2
( IlyasS. MoncrieffJ. (2012). Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. The British Journal of Psychiatry, 200(5), 393–398.22442100)
IlyasS. MoncrieffJ. (2012). Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. The British Journal of Psychiatry, 200(5), 393–398.22442100IlyasS. MoncrieffJ. (2012). Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. The British Journal of Psychiatry, 200(5), 393–398.22442100, IlyasS. MoncrieffJ. (2012). Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. The British Journal of Psychiatry, 200(5), 393–398.22442100
( ThaparA. CooperM. (2016). Attention deficit hyperactivity disorder. The Lancet, 387(10024), 1240–1250.)
ThaparA. CooperM. (2016). Attention deficit hyperactivity disorder. The Lancet, 387(10024), 1240–1250.ThaparA. CooperM. (2016). Attention deficit hyperactivity disorder. The Lancet, 387(10024), 1240–1250., ThaparA. CooperM. (2016). Attention deficit hyperactivity disorder. The Lancet, 387(10024), 1240–1250.
( CoghillD. BanaschewskiT. LegendreuxM. SoutulloC. JohnsonM. ZuddasA. AndersonC. CivilR. HigginsN. LyneA. SquiresL. (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23(10), 1208–1218.23332456)
CoghillD. BanaschewskiT. LegendreuxM. SoutulloC. JohnsonM. ZuddasA. AndersonC. CivilR. HigginsN. LyneA. SquiresL. (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23(10), 1208–1218.23332456CoghillD. BanaschewskiT. LegendreuxM. SoutulloC. JohnsonM. ZuddasA. AndersonC. CivilR. HigginsN. LyneA. SquiresL. (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23(10), 1208–1218.23332456, CoghillD. BanaschewskiT. LegendreuxM. SoutulloC. JohnsonM. ZuddasA. AndersonC. CivilR. HigginsN. LyneA. SquiresL. (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23(10), 1208–1218.23332456
( Bank of England. (2020). Inflation calculator. https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator)
Bank of England. (2020). Inflation calculator. https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculatorBank of England. (2020). Inflation calculator. https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator, Bank of England. (2020). Inflation calculator. https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator
( Yellow Card. (2020). Interactive drug analysis profiles. https://yellowcard.mhra.gov.uk/iDAP/)
Yellow Card. (2020). Interactive drug analysis profiles. https://yellowcard.mhra.gov.uk/iDAP/Yellow Card. (2020). Interactive drug analysis profiles. https://yellowcard.mhra.gov.uk/iDAP/, Yellow Card. (2020). Interactive drug analysis profiles. https://yellowcard.mhra.gov.uk/iDAP/
(2020)
Inflation calculator
J. Frampton (2018)
Lisdexamfetamine Dimesylate: A Review in Paediatric ADHDDrugs, 78
D. Coghill, T. Banaschewski, M. Lecendreux, C. Soutullo, Mats Johnson, A. Zuddas, C. Anderson, R. Civil, N. Higgins, A. Lyne, L. Squires (2013)
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorderEuropean Neuropsychopharmacology, 23
E. Zimovetz, A. Joseph, R. Ayyagari, J. Mauskopf (2017)
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UKThe European Journal of Health Economics, 19
(2019)
Prescription Cost Analysis (PCA) data
(2020)
Let’s talk about cost
( National Institute for Health and Care Excellence (NICE). (2019). Attention deficit hyperactivity disorder: Diagnosis and management (update). https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933)
National Institute for Health and Care Excellence (NICE). (2019). Attention deficit hyperactivity disorder: Diagnosis and management (update). https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933National Institute for Health and Care Excellence (NICE). (2019). Attention deficit hyperactivity disorder: Diagnosis and management (update). https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933, National Institute for Health and Care Excellence (NICE). (2019). Attention deficit hyperactivity disorder: Diagnosis and management (update). https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933
( FayyadJ. SampsonN. A. HwangI. AdamowskiT. Aguilar-GaxiolaS. Al-HamzawiA. AndradeL. H. S. BorgesG. de GirolamoG. FlorescuS. GurejeO. HaroJ. M. HuC. KaramE. G. LeeS. Navarro-MateuF. O’NeillS. PennellB-E. PiazzaM. , . . . KesslerR. C. (2017). The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. ADHD Attention Deficit and Hyperactivity Disorders, 2017; 9(1), 47–65.27866355)
FayyadJ. SampsonN. A. HwangI. AdamowskiT. Aguilar-GaxiolaS. Al-HamzawiA. AndradeL. H. S. BorgesG. de GirolamoG. FlorescuS. GurejeO. HaroJ. M. HuC. KaramE. G. LeeS. Navarro-MateuF. O’NeillS. PennellB-E. PiazzaM. , . . . KesslerR. C. (2017). The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. ADHD Attention Deficit and Hyperactivity Disorders, 2017; 9(1), 47–65.27866355FayyadJ. SampsonN. A. HwangI. AdamowskiT. Aguilar-GaxiolaS. Al-HamzawiA. AndradeL. H. S. BorgesG. de GirolamoG. FlorescuS. GurejeO. HaroJ. M. HuC. KaramE. G. LeeS. Navarro-MateuF. O’NeillS. PennellB-E. PiazzaM. , . . . KesslerR. C. (2017). The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. ADHD Attention Deficit and Hyperactivity Disorders, 2017; 9(1), 47–65.27866355, FayyadJ. SampsonN. A. HwangI. AdamowskiT. Aguilar-GaxiolaS. Al-HamzawiA. AndradeL. H. S. BorgesG. de GirolamoG. FlorescuS. GurejeO. HaroJ. M. HuC. KaramE. G. LeeS. Navarro-MateuF. O’NeillS. PennellB-E. PiazzaM. , . . . KesslerR. C. (2017). The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. ADHD Attention Deficit and Hyperactivity Disorders, 2017; 9(1), 47–65.27866355
( BolandF. GalvinR. ReulbachU. MotterliniN. KellyD. BennettK. FaheyT. (2015). Psychostimulant prescribing trends in a paediatric population in Ireland: A national cohort study. BMC Paediatrics, 15(1), 118.)
BolandF. GalvinR. ReulbachU. MotterliniN. KellyD. BennettK. FaheyT. (2015). Psychostimulant prescribing trends in a paediatric population in Ireland: A national cohort study. BMC Paediatrics, 15(1), 118.BolandF. GalvinR. ReulbachU. MotterliniN. KellyD. BennettK. FaheyT. (2015). Psychostimulant prescribing trends in a paediatric population in Ireland: A national cohort study. BMC Paediatrics, 15(1), 118., BolandF. GalvinR. ReulbachU. MotterliniN. KellyD. BennettK. FaheyT. (2015). Psychostimulant prescribing trends in a paediatric population in Ireland: A national cohort study. BMC Paediatrics, 15(1), 118.
( FramptonJ. E. (2018). Lisdexamfetamine dimesylate: A review in paediatric ADHD. Drugs, 78(10), 1025–1036.29923015)
FramptonJ. E. (2018). Lisdexamfetamine dimesylate: A review in paediatric ADHD. Drugs, 78(10), 1025–1036.29923015FramptonJ. E. (2018). Lisdexamfetamine dimesylate: A review in paediatric ADHD. Drugs, 78(10), 1025–1036.29923015, FramptonJ. E. (2018). Lisdexamfetamine dimesylate: A review in paediatric ADHD. Drugs, 78(10), 1025–1036.29923015
( British National Formulary (BNF). (2019). Lisdexamfetamine. https://www-medicinescomplete-com.libaccess.hud.ac.uk/#/content/bnf/_627757297#content%2Fbnf%2F_627757297%23pot-medicines)
British National Formulary (BNF). (2019). Lisdexamfetamine. https://www-medicinescomplete-com.libaccess.hud.ac.uk/#/content/bnf/_627757297#content%2Fbnf%2F_627757297%23pot-medicinesBritish National Formulary (BNF). (2019). Lisdexamfetamine. https://www-medicinescomplete-com.libaccess.hud.ac.uk/#/content/bnf/_627757297#content%2Fbnf%2F_627757297%23pot-medicines, British National Formulary (BNF). (2019). Lisdexamfetamine. https://www-medicinescomplete-com.libaccess.hud.ac.uk/#/content/bnf/_627757297#content%2Fbnf%2F_627757297%23pot-medicines
Muhammed Ather, G. Salmon (2018)
Attention deficit hyperactivity disorder.British journal of hospital medicine, 71 11
R. Griffith (2009)
Community midwives and the safer management of controlled drugsThe British Journal of Midwifery, 17
( SchefflerR. M. HinshawS. P. ModrekS. LevineP. (2007). The global market for ADHD medications. Health Affairs, 26(2), 450–457.17339673)
SchefflerR. M. HinshawS. P. ModrekS. LevineP. (2007). The global market for ADHD medications. Health Affairs, 26(2), 450–457.17339673SchefflerR. M. HinshawS. P. ModrekS. LevineP. (2007). The global market for ADHD medications. Health Affairs, 26(2), 450–457.17339673, SchefflerR. M. HinshawS. P. ModrekS. LevineP. (2007). The global market for ADHD medications. Health Affairs, 26(2), 450–457.17339673
( RenouxC. ShinJ. Y. Dell’AnielloS. FergussonE. SuissaS. (2016). Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. British Journal of Clinical Pharmacology, 82(3), 858–868.27145886)
RenouxC. ShinJ. Y. Dell’AnielloS. FergussonE. SuissaS. (2016). Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. British Journal of Clinical Pharmacology, 82(3), 858–868.27145886RenouxC. ShinJ. Y. Dell’AnielloS. FergussonE. SuissaS. (2016). Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. British Journal of Clinical Pharmacology, 82(3), 858–868.27145886, RenouxC. ShinJ. Y. Dell’AnielloS. FergussonE. SuissaS. (2016). Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. British Journal of Clinical Pharmacology, 82(3), 858–868.27145886
( National Institute for Health and Care Excellence (NICE). (2018a). Attention deficit hyperactivity disorder. https://www.nice.org.uk/guidance/ng87/evidence/full-guideline-pdf-4783651311)
National Institute for Health and Care Excellence (NICE). (2018a). Attention deficit hyperactivity disorder. https://www.nice.org.uk/guidance/ng87/evidence/full-guideline-pdf-4783651311National Institute for Health and Care Excellence (NICE). (2018a). Attention deficit hyperactivity disorder. https://www.nice.org.uk/guidance/ng87/evidence/full-guideline-pdf-4783651311, National Institute for Health and Care Excellence (NICE). (2018a). Attention deficit hyperactivity disorder. https://www.nice.org.uk/guidance/ng87/evidence/full-guideline-pdf-4783651311
( National Institute for Health and Care Excellence (NICE). (2018b). Attention deficit hyperactivity disorder (update): Evidence reviews for pharmacological efficacy and sequencing pharmacological treatment. https://www.nice.org.uk/guidance/ng87/evidence/c-pharmacological-efficacy-and-sequencing-pdf-4783686303)
National Institute for Health and Care Excellence (NICE). (2018b). Attention deficit hyperactivity disorder (update): Evidence reviews for pharmacological efficacy and sequencing pharmacological treatment. https://www.nice.org.uk/guidance/ng87/evidence/c-pharmacological-efficacy-and-sequencing-pdf-4783686303National Institute for Health and Care Excellence (NICE). (2018b). Attention deficit hyperactivity disorder (update): Evidence reviews for pharmacological efficacy and sequencing pharmacological treatment. https://www.nice.org.uk/guidance/ng87/evidence/c-pharmacological-efficacy-and-sequencing-pdf-4783686303, National Institute for Health and Care Excellence (NICE). (2018b). Attention deficit hyperactivity disorder (update): Evidence reviews for pharmacological efficacy and sequencing pharmacological treatment. https://www.nice.org.uk/guidance/ng87/evidence/c-pharmacological-efficacy-and-sequencing-pdf-4783686303
F. Boland, R. Galvin, U. Reulbach, N. Motterlini, D. Kelly, K. Bennett, T. Fahey (2015)
Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort studyBMC Pediatrics, 15
( Beau-LejdstromR. DouglasI. EvansS. J. SmeethL. (2016). Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. BMJ Open, 6(6), e010508.)
Beau-LejdstromR. DouglasI. EvansS. J. SmeethL. (2016). Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. BMJ Open, 6(6), e010508.Beau-LejdstromR. DouglasI. EvansS. J. SmeethL. (2016). Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. BMJ Open, 6(6), e010508., Beau-LejdstromR. DouglasI. EvansS. J. SmeethL. (2016). Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. BMJ Open, 6(6), e010508.
( KrelingD. H. MottD. A. WiederholtJ. B. LundyJ. LevittL. (2001). Prescription drug trends: A chartbook. Kaiser Family Foundation. http://files.kff.org/attachment/report-prescription-drug-trends-a-chartbook-update)
KrelingD. H. MottD. A. WiederholtJ. B. LundyJ. LevittL. (2001). Prescription drug trends: A chartbook. Kaiser Family Foundation. http://files.kff.org/attachment/report-prescription-drug-trends-a-chartbook-updateKrelingD. H. MottD. A. WiederholtJ. B. LundyJ. LevittL. (2001). Prescription drug trends: A chartbook. Kaiser Family Foundation. http://files.kff.org/attachment/report-prescription-drug-trends-a-chartbook-update, KrelingD. H. MottD. A. WiederholtJ. B. LundyJ. LevittL. (2001). Prescription drug trends: A chartbook. Kaiser Family Foundation. http://files.kff.org/attachment/report-prescription-drug-trends-a-chartbook-update
I. Hernandez, A. San-Juan-Rodriguez, C. Good, W. Gellad (2020)
Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.JAMA, 323 9
S. Cortese, N. Adamo, C. Giovane, Christina Mohr-Jensen, A. Hayes, S. Carucci, L. Atkinson, Luca Tessari, T. Banaschewski, D. Coghill, C. Hollis, E. Simonoff, A. Zuddas, C. Barbui, M. Purgato, H. Steinhausen, F. Shokraneh, Jun Xia, A. Cipriani (2018)
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysisThe Lancet. Psychiatry, 5
J. Fayyad, N. Sampson, I. Hwang, T. Adamowski, S. Aguilar-Gaxiola, A. Al-Hamzawi, L. Andrade, G. Borges, G. Girolamo, S. Florescu, O. Gureje, J. Haro, Chi‐yi Hu, E. Karam, Sing Lee, F. Navarro-Mateu, S. O’neill, B. Pennell, M. Piazza, J. Posada-Villa, M. Have, Y. Torres, M. Xavier, A. Zaslavsky, R. Kessler, On Collaborators (2017)
The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health SurveysADHD Attention Deficit and Hyperactivity Disorders, 9
Sudha Raman, Kenneth Man, S. Bahmanyar, A. Bérard, S. Bilder, Takoua Boukhris, G. Bushnell, S. Crystal, K. Furu, Yea-Huei KaoYang, Ø. Karlstad, H. Kieler, K. Kubota, E. Lai, J. Martikainen, Géric Maura, N. Moore, D. Montero, Hidefumi Nakamura, A. Neumann, V. Pate, A. Pottegård, N. Pratt, E. Roughead, D. Saint-Gerons, T. Stürmer, Chien-Chou Su, H. Zoega, Miriam Sturkenbroom, E. Chan, D. Coghill, P. Ip, I. Wong (2018)
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.The lancet. Psychiatry, 5 10
T. Nøvik, A. Hervás, Stephen Ralston, S. Dalsgaard, R. Pereira, M. Lorenzo, Adore Group (2006)
Influence of gender on Attention-Deficit/Hyperactivity Disorder in Europe – ADOREEuropean Child & Adolescent Psychiatry, 15
( Pharmaceutical Research and Manufacturers of America (2020). Let’s talk about cost. https://www.letstalkaboutcost.org/)
Pharmaceutical Research and Manufacturers of America (2020). Let’s talk about cost. https://www.letstalkaboutcost.org/Pharmaceutical Research and Manufacturers of America (2020). Let’s talk about cost. https://www.letstalkaboutcost.org/, Pharmaceutical Research and Manufacturers of America (2020). Let’s talk about cost. https://www.letstalkaboutcost.org/
V. Mittal, E. Walker (2011)
Diagnostic and Statistical Manual of Mental DisordersPsychiatry Research, 189
R. Scheffler, S. Hinshaw, S. Modrek, P. Levine (2007)
The global market for ADHD medications.Health affairs, 26 2
(2001)
Prescription drug trends: A chartbook
B. Bolea-Alamañac, D. Nutt, M. Adamou, P. Asherson, S. Bazire, D. Coghill, D. Heal, U. Müller, J. Nash, P. Santosh, K. Sayal, E. Sonuga-Barke, S. Young (2014)
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology, 28
( NHS Digital. (2019). Prescription cost analysis – England 2018. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018)
NHS Digital. (2019). Prescription cost analysis – England 2018. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018NHS Digital. (2019). Prescription cost analysis – England 2018. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018, NHS Digital. (2019). Prescription cost analysis – England 2018. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018
Raphaelle Beau-Lejdstrom, I. Douglas, S. Evans, L. Smeeth (2016)
Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistenceBMJ Open, 6
Stephen Ilyas, J. Moncrieff (2012)
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.The British journal of psychiatry : the journal of mental science, 200 5
( ZimovetzE. A. JosephA. AyyagariR. MauskopfJ. A. (2018). A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European Journal of Health Economics, 19(1), 21–35.28093662)
ZimovetzE. A. JosephA. AyyagariR. MauskopfJ. A. (2018). A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European Journal of Health Economics, 19(1), 21–35.28093662ZimovetzE. A. JosephA. AyyagariR. MauskopfJ. A. (2018). A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European Journal of Health Economics, 19(1), 21–35.28093662, ZimovetzE. A. JosephA. AyyagariR. MauskopfJ. A. (2018). A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European Journal of Health Economics, 19(1), 21–35.28093662
C. Renoux, Ju-Young Shin, S. Dell'aniello, E. Fergusson, S. Suissa (2016)
Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015.British journal of clinical pharmacology, 82 3
( HernandezI. San-Juan-RodriguezA. GoodC. B. GelladW. F. (2020). Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018. JAMA, 323(9), 854–862.32125403)
HernandezI. San-Juan-RodriguezA. GoodC. B. GelladW. F. (2020). Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018. JAMA, 323(9), 854–862.32125403HernandezI. San-Juan-RodriguezA. GoodC. B. GelladW. F. (2020). Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018. JAMA, 323(9), 854–862.32125403, HernandezI. San-Juan-RodriguezA. GoodC. B. GelladW. F. (2020). Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018. JAMA, 323(9), 854–862.32125403
(2020)
Tariff prices for Dexamfetamine 5mg tablets
( NøvikT. S. HervasA. RalstonS. J. DalsgaardS. PereiraR. R. LorenzoM. J. , & ADORE Study Group. (2006). Influence of gender on attention-deficit/hyperactivity disorder in Europe - ADORE. European Child and Adolescent Psychiatry, 15(Suppl. 1), i15–i24.)
NøvikT. S. HervasA. RalstonS. J. DalsgaardS. PereiraR. R. LorenzoM. J. , & ADORE Study Group. (2006). Influence of gender on attention-deficit/hyperactivity disorder in Europe - ADORE. European Child and Adolescent Psychiatry, 15(Suppl. 1), i15–i24.NøvikT. S. HervasA. RalstonS. J. DalsgaardS. PereiraR. R. LorenzoM. J. , & ADORE Study Group. (2006). Influence of gender on attention-deficit/hyperactivity disorder in Europe - ADORE. European Child and Adolescent Psychiatry, 15(Suppl. 1), i15–i24., NøvikT. S. HervasA. RalstonS. J. DalsgaardS. PereiraR. R. LorenzoM. J. , & ADORE Study Group. (2006). Influence of gender on attention-deficit/hyperactivity disorder in Europe - ADORE. European Child and Adolescent Psychiatry, 15(Suppl. 1), i15–i24.
( The NHS Business Services Authority (NHSBSA). (2019). Prescription Cost Analysis (PCA) data. https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data)
The NHS Business Services Authority (NHSBSA). (2019). Prescription Cost Analysis (PCA) data. https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-dataThe NHS Business Services Authority (NHSBSA). (2019). Prescription Cost Analysis (PCA) data. https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data, The NHS Business Services Authority (NHSBSA). (2019). Prescription Cost Analysis (PCA) data. https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data
( TurgayA. GoodmanD. W. AshersonP. LasserR. A. BabcockT. F. PucciM. L. BarkleyR. , & ADHD Transition Phase Model Working Group. (2012). Lifespan persistence of ADHD: The life transition model and its application. The Journal of Clinical Psychiatry, 73(2), 192–201.22313720)
TurgayA. GoodmanD. W. AshersonP. LasserR. A. BabcockT. F. PucciM. L. BarkleyR. , & ADHD Transition Phase Model Working Group. (2012). Lifespan persistence of ADHD: The life transition model and its application. The Journal of Clinical Psychiatry, 73(2), 192–201.22313720TurgayA. GoodmanD. W. AshersonP. LasserR. A. BabcockT. F. PucciM. L. BarkleyR. , & ADHD Transition Phase Model Working Group. (2012). Lifespan persistence of ADHD: The life transition model and its application. The Journal of Clinical Psychiatry, 73(2), 192–201.22313720, TurgayA. GoodmanD. W. AshersonP. LasserR. A. BabcockT. F. PucciM. L. BarkleyR. , & ADHD Transition Phase Model Working Group. (2012). Lifespan persistence of ADHD: The life transition model and its application. The Journal of Clinical Psychiatry, 73(2), 192–201.22313720
Objective: We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. Methods: The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. Results: The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p = .001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p = .001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. Conclusion: The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.
Journal of Attention Disorders: A Journal of Theoretical and Applied Science – SAGE
Published: Mar 5, 2021
Keywords: adverse drug reactions; attention deficit hyperactivity disorder; cost; England; prescriptions
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.